???pagination.result.count???
Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/ NR2A and NR1/ NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission. , Frizelle PA, Chen PE, Wyllie DJ., Mol Pharmacol. September 1, 2006; 70 (3): 1022-32.
A genetically modified mouse model probing the selective action of ifenprodil at the N-methyl-D-aspartate type 2B receptor. , Rosahl TW, Wingrove PB, Hunt V, Fradley RL, Lawrence JM, Heavens RP, Treacey P, Usala M, Macaulay A, Bonnert TP, Whiting PJ, Wafford KA., Mol Cell Neurosci. September 1, 2006; 33 (1): 47-56.
Differential modulation of human N-methyl-D-aspartate receptors by structurally diverse general anesthetics. , Solt K, Eger EI, Raines DE., Anesth Analg. May 1, 2006; 102 (5): 1407-11.
Nickel differentially affects NMDA receptor channels in developing cultured rat neurons. , Gavazzo P, Mazzolini M, Tedesco M, Marchetti C., Dev Biol. March 17, 2006; 1078 (1): 71-9.
NMDA receptor subunit-dependent modulation by conantokin-G and Ala7-conantokin-G. , Ragnarsson L, Yasuda T, Lewis RJ, Dodd PR, Adams DJ., J Neurochem. January 1, 2006; 96 (1): 283-91.
Tweaking agonist efficacy at N-methyl-D-aspartate receptors by site-directed mutagenesis. , Hansen KB, Clausen RP, Bjerrum EJ, Bechmann C, Greenwood JR, Christensen C, Kristensen JL, Egebjerg J, Bräuner-Osborne H., Mol Pharmacol. December 1, 2005; 68 (6): 1510-23.
CaMKII tethers to L-type Ca2+ channels, establishing a local and dedicated integrator of Ca2+ signals for facilitation. , Hudmon A, Schulman H, Kim J , Maltez JM, Tsien RW, Pitt GS., J Cell Biol. November 7, 2005; 171 (3): 537-47.
NMDA receptors as targets of heavy metal interaction and toxicity. , Marchetti C, Gavazzo P., Neurotox Res. November 1, 2005; 8 (3-4): 245-58.
Multivalent interactions of calcium/calmodulin-dependent protein kinase II with the postsynaptic density proteins NR2B, densin-180, and alpha- actinin-2. , Robison AJ, Bass MA, Jiao Y, MacMillan LB, Carmody LC, Bartlett RK, Colbran RJ., J Biol Chem. October 21, 2005; 280 (42): 35329-36.
Synthesis, binding affinity at glutamic acid receptors, neuroprotective effects, and molecular modeling investigation of novel dihydroisoxazole amino acids. , Conti P, De Amici M, Grazioso G, Roda G, Pinto A, Hansen KB, Nielsen B, Madsen U, Bräuner-Osborne H, Egebjerg J, Vestri V, Pellegrini-Giampietro DE, Sibille P, Acher FC, De Micheli C., J Med Chem. October 6, 2005; 48 (20): 6315-25.
Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket. , Kinarsky L, Feng B, Skifter DA, Morley RM, Sherman S, Jane DE, Monaghan DT., J Pharmacol Exp Ther. June 1, 2005; 313 (3): 1066-74.
Corymine potentiates NMDA-induced currents in Xenopus oocytes expressing NR1a/ NR2B glutamate receptors. , Leewanich P, Tohda M, Takayama H, Sophasan S, Watanabe H, Matsumoto K ., J Pharmacol Sci. May 1, 2005; 98 (1): 58-65.
Modulation of triheteromeric NMDA receptors by N-terminal domain ligands. , Hatton CJ, Paoletti P., Neuron. April 21, 2005; 46 (2): 261-74.
Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. , Morley RM, Tse HW, Feng B, Miller JC, Monaghan DT, Jane DE., J Med Chem. April 7, 2005; 48 (7): 2627-37.
PKC site mutations reveal differential modulation by insulin of NMDA receptors containing NR2A or NR2B subunits. , Jones ML, Leonard JP., J Neurochem. March 1, 2005; 92 (6): 1431-8.
The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. , Feng B, Morley RM, Jane DE, Monaghan DT., Neuropharmacology. March 1, 2005; 48 (3): 354-9.
The micromolar zinc-binding domain on the NMDA receptor subunit NR2B. , Rachline J, Perin-Dureau F, Le Goff A, Neyton J, Paoletti P., J Neurosci. January 12, 2005; 25 (2): 308-17.
Monoamines directly inhibit N-methyl-D-aspartate receptors expressed in Xenopus oocytes in a voltage-dependent manner. , Masuko T, Suzuki I, Kizawa Y, Kusama-Eguchi K, Watanabe K , Kashiwagi K , Igarashi K, Kusama T., Neurosci Lett. November 16, 2004; 371 (1): 30-3.
Endocytosis and degradative sorting of NMDA receptors by conserved membrane- proximal signals. , Scott DB, Michailidis I, Mu Y, Logothetis D, Ehlers MD., J Neurosci. August 11, 2004; 24 (32): 7096-109.
Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-[8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)- en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride). , Sun L, Chiu D, Kowal D, Simon R, Smeyne M, Zukin RS, Olney J, Baudy R, Lin S., J Pharmacol Exp Ther. August 1, 2004; 310 (2): 563-70.
Extrasynaptic NR2B and NR2D subunits of NMDA receptors shape 'superslow' afterburst EPSC in rat hippocampus. , Lozovaya NA, Grebenyuk SE, Tsintsadze TSh, Feng B, Monaghan DT, Krishtal OA., J Physiol. July 15, 2004; 558 (Pt 2): 451-63.
Anthraquinone polyamines: novel channel blockers to study N-methyl-D-aspartate receptors. , Kashiwagi K , Tanaka I, Tamura M, Sugiyama H, Okawara T, Otsuka M, Sabado TN, Williams K, Igarashi K., J Pharmacol Exp Ther. June 1, 2004; 309 (3): 884-93.
A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity. , Jang MK, Mierke DF, Russek SJ, Farb DH., Proc Natl Acad Sci U S A. May 25, 2004; 101 (21): 8198-8203.
Differential modulation of NR1- NR2A and NR1- NR2B subtypes of NMDA receptor by PDZ domain-containing proteins. , Iwamoto T, Yamada Y, Hori K, Watanabe Y, Sobue K, Inui M., J Neurochem. April 1, 2004; 89 (1): 100-8.
Structure-activity analysis of a novel NR2C/ NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. , Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT., Br J Pharmacol. February 1, 2004; 141 (3): 508-16.
Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket. , Malherbe P, Mutel V, Broger C, Perin-Dureau F, Kemp JA, Neyton J, Paoletti P, Kew JN., J Pharmacol Exp Ther. December 1, 2003; 307 (3): 897-905.
Clozapine inhibits isolated N-methyl-D-aspartate receptors expressed in xenopus oocytes in a subunit specific manner. , Levine JB, Martin G, Wilson A, Treistman SN., Neurosci Lett. August 7, 2003; 346 (3): 125-8.
Structural model of the N-methyl-D-aspartate receptor glycine site probed by site-directed chemical coupling. , Foucaud B, Laube B, Schemm R, Kreimeyer A, Goeldner M, Betz H., J Biol Chem. June 27, 2003; 278 (26): 24011-7.
ATP inhibits NMDA receptors after heterologous expression and in cultured hippocampal neurons and attenuates NMDA-mediated neurotoxicity. , Ortinau S, Laube B, Zimmermann H., J Neurosci. June 15, 2003; 23 (12): 4996-5003.
Activation of NR1a/ NR2B receptors by monocyte-derived macrophage secretory products: implications for human immunodeficiency virus type one-associated dementia. , Xiong H, McCabe L, Skifter D, Monaghan DT, Gendelman HE., Neurosci Lett. May 8, 2003; 341 (3): 246-50.
Pharmacology of delta2 glutamate receptors: effects of pentamidine and protons. , Williams K, Dattilo M, Sabado TN, Kashiwagi K , Igarashi K., J Pharmacol Exp Ther. May 1, 2003; 305 (2): 740-8.
Oxygen sensitivity of NMDA receptors: relationship to NR2 subunit composition and hypoxia tolerance of neonatal neurons. , Bickler PE, Fahlman CS, Taylor DM., Neuroscience. January 1, 2003; 118 (1): 25-35.
Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. , Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet-Trafit B, Lorez HP, Malherbe P, Miss MT, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht R, Wyler R, Kemp JA., J Pharmacol Exp Ther. September 1, 2002; 302 (3): 940-8.
N-Methyl-D-aspartate receptor subtype-selectivity of homoquinolinate: an electrophysiological and radioligand binding study using both native and recombinant receptors. , Grimwood S, Wafford KA, Macaulay A, Hutson PH., J Neurochem. August 1, 2002; 82 (4): 794-800.
Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. , Perin-Dureau F, Rachline J, Neyton J, Paoletti P., J Neurosci. July 15, 2002; 22 (14): 5955-65.
Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. , Kashiwagi K , Masuko T, Nguyen CD, Kuno T, Tanaka I, Igarashi K, Williams K., Mol Pharmacol. March 1, 2002; 61 (3): 533-45.
Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. , Malayev A, Gibbs TT, Farb DH., Br J Pharmacol. February 1, 2002; 135 (4): 901-9.
Specificity of putative partial agonist, 1-aminocyclopropanecarboxylic acid, for rat N-methyl-D-aspartate receptor subunits. , Sheinin A, Nahum-Levy R, Shavit S, Benveniste M., Neurosci Lett. January 11, 2002; 317 (2): 77-80.
Ethanol inhibition of N-methyl-D-aspartate receptors is reduced by site-directed mutagenesis of a transmembrane domain phenylalanine residue. , Ronald KM, Mirshahi T, Woodward JJ., J Biol Chem. November 30, 2001; 276 (48): 44729-35.
Point mutations identify the glutamate binding pocket of the N-methyl-D-aspartate receptor as major site of conantokin-G inhibition. , Wittekindt B, Malany S, Schemm R, Otvos L, Maccecchini ML, Laube B, Betz H., Neuropharmacology. November 1, 2001; 41 (6): 753-61.
Lead inhibition of NMDA channels in native and recombinant receptors. , Gavazzo P, Gazzoli A, Mazzolini M, Marchetti C., Neuroreport. October 8, 2001; 12 (14): 3121-5.
Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. , Sheinin A, Shavit S, Benveniste M., Neuropharmacology. August 1, 2001; 41 (2): 151-8.
The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. , Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E, Spanagel R, Zieglgänsberger W, Schadrack J., Neuropharmacology. May 1, 2001; 40 (6): 749-60.
Evidence for direct protein kinase-C mediated modulation of N-methyl-D-aspartate receptor current. , Liao GY, Wagner DA, Hsu MH, Leonard JP., Mol Pharmacol. May 1, 2001; 59 (5): 960-4.
K(+) occupancy of the N-methyl-d-aspartate receptor channel probed by Mg(2+) block. , Zhu Y, Auerbach A., J Gen Physiol. March 1, 2001; 117 (3): 287-98.
Na(+) occupancy and Mg(2+) block of the n-methyl-d-aspartate receptor channel. , Zhu Y, Auerbach A., J Gen Physiol. March 1, 2001; 117 (3): 275-86.
Use of trifluoroperazine isolates a [(3)H]Ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits. , Coughenour LL, Barr BM., J Pharmacol Exp Ther. January 1, 2001; 296 (1): 150-9.
Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors. , Donevan SD, McCabe RT., Mol Pharmacol. September 1, 2000; 58 (3): 614-23.
Modulation of hypothalamic NMDA receptor function by cyclic AMP-dependent protein kinase and phosphatases. , Nijholt I, Blank T, Liu A, Kügler H, Spiess J., J Neurochem. August 1, 2000; 75 (2): 749-54.
In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus. , White HS, McCabe RT, Armstrong H, Donevan SD, Cruz LJ, Abogadie FC, Torres J, Rivier JE, Paarmann I, Hollmann M, Olivera BM., J Pharmacol Exp Ther. January 1, 2000; 292 (1): 425-32.